nodes	percent_of_prediction	percent_of_DWPC	metapath
Regadenoson—S-Adenosylmethionine—GNMT—prostate cancer	0.00676	0.274	CrCbGaD
Regadenoson—Azacitidine—DNMT1—prostate cancer	0.00429	0.174	CrCbGaD
Regadenoson—Adenosine triphosphate—HSPA1A—prostate cancer	0.00382	0.155	CrCbGaD
Regadenoson—S-Adenosylmethionine—COMT—prostate cancer	0.00173	0.0703	CrCbGaD
Regadenoson—Adenosine monophosphate—PDE4D—prostate cancer	0.00169	0.0684	CrCbGaD
Regadenoson—Adenosine triphosphate—AKT1—prostate cancer	0.0015	0.0606	CrCbGaD
Regadenoson—Adenosine monophosphate—SRC—prostate cancer	0.00147	0.0598	CrCbGaD
Regadenoson—Cytarabine—SLC22A1—prostate cancer	0.00115	0.0466	CrCbGaD
Regadenoson—Cladribine—SLC22A1—prostate cancer	0.00106	0.0428	CrCbGaD
Regadenoson—S-Adenosylmethionine—CYP2E1—prostate cancer	0.000807	0.0327	CrCbGaD
Regadenoson—ADORA2A—Signaling by GPCR—RGS17—prostate cancer	0.000521	0.00479	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—PRKACB—prostate cancer	0.000519	0.00478	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—FGF10—prostate cancer	0.000514	0.00473	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—RLN2—prostate cancer	0.000511	0.0047	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—GNRH1—prostate cancer	0.000496	0.00456	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—ITPR1—prostate cancer	0.000481	0.00443	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—LPAR1—prostate cancer	0.00048	0.00442	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—GRP—prostate cancer	0.00048	0.00442	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—SIRT1—prostate cancer	0.000478	0.0044	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—FGFR4—prostate cancer	0.000473	0.00435	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—PLXNB1—prostate cancer	0.000468	0.0043	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—CX3CL1—prostate cancer	0.000466	0.00429	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—RLN2—prostate cancer	0.000464	0.00427	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—ANXA1—prostate cancer	0.000464	0.00427	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—TYMS—prostate cancer	0.000464	0.00427	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—GRPR—prostate cancer	0.00045	0.00414	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—PDGFRB—prostate cancer	0.000437	0.00402	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—GNG5—prostate cancer	0.000431	0.00397	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—CASP9—prostate cancer	0.000429	0.00395	CbGpPWpGaD
Regadenoson—Malaise—Capecitabine—prostate cancer	0.000425	0.000491	CcSEcCtD
Regadenoson—Somnolence—Etoposide—prostate cancer	0.000425	0.000491	CcSEcCtD
Regadenoson—Cough—Docetaxel—prostate cancer	0.000425	0.00049	CcSEcCtD
Regadenoson—Angina pectoris—Doxorubicin—prostate cancer	0.000425	0.00049	CcSEcCtD
Regadenoson—ADORA2A—GPCRs, Class A Rhodopsin-like—ADRB2—prostate cancer	0.000425	0.00391	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PLXNB1—prostate cancer	0.000425	0.00391	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CXCL12—prostate cancer	0.000424	0.0039	CbGpPWpGaD
Regadenoson—Hypersensitivity—Mitoxantrone—prostate cancer	0.000424	0.000489	CcSEcCtD
Regadenoson—Syncope—Capecitabine—prostate cancer	0.000423	0.000488	CcSEcCtD
Regadenoson—Mental disorder—Prednisone—prostate cancer	0.000423	0.000488	CcSEcCtD
Regadenoson—Diarrhoea—Estradiol—prostate cancer	0.000422	0.000487	CcSEcCtD
Regadenoson—Convulsion—Docetaxel—prostate cancer	0.000422	0.000487	CcSEcCtD
Regadenoson—Hypertension—Docetaxel—prostate cancer	0.00042	0.000485	CcSEcCtD
Regadenoson—Erythema—Prednisone—prostate cancer	0.00042	0.000485	CcSEcCtD
Regadenoson—Palpitations—Capecitabine—prostate cancer	0.000417	0.000481	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—NGFR—prostate cancer	0.000416	0.00383	CbGpPWpGaD
Regadenoson—Myalgia—Docetaxel—prostate cancer	0.000415	0.000478	CcSEcCtD
Regadenoson—Chest pain—Docetaxel—prostate cancer	0.000415	0.000478	CcSEcCtD
Regadenoson—Arthralgia—Docetaxel—prostate cancer	0.000415	0.000478	CcSEcCtD
Regadenoson—Loss of consciousness—Capecitabine—prostate cancer	0.000414	0.000478	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—ERBB3—prostate cancer	0.000413	0.0038	CbGpPWpGaD
Regadenoson—Renal failure—Epirubicin—prostate cancer	0.000413	0.000477	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Etoposide—prostate cancer	0.000413	0.000476	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—FGFR2—prostate cancer	0.000413	0.0038	CbGpPWpGaD
Regadenoson—Asthenia—Mitoxantrone—prostate cancer	0.000413	0.000476	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	0.000412	0.000475	CcSEcCtD
Regadenoson—Cough—Capecitabine—prostate cancer	0.000411	0.000475	CcSEcCtD
Regadenoson—Pain—Etoposide—prostate cancer	0.000409	0.000472	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—GRPR—prostate cancer	0.000409	0.00376	CbGpPWpGaD
Regadenoson—Dizziness—Estradiol—prostate cancer	0.000408	0.000471	CcSEcCtD
Regadenoson—Hypertension—Capecitabine—prostate cancer	0.000407	0.00047	CcSEcCtD
Regadenoson—Arthralgia—Capecitabine—prostate cancer	0.000401	0.000463	CcSEcCtD
Regadenoson—Myalgia—Capecitabine—prostate cancer	0.000401	0.000463	CcSEcCtD
Regadenoson—Chest pain—Capecitabine—prostate cancer	0.000401	0.000463	CcSEcCtD
Regadenoson—Cytarabine—CYP3A4—prostate cancer	0.000401	0.0163	CrCbGaD
Regadenoson—Anxiety—Capecitabine—prostate cancer	0.0004	0.000462	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	0.000399	0.00046	CcSEcCtD
Regadenoson—Anaphylactic shock—Docetaxel—prostate cancer	0.000397	0.000459	CcSEcCtD
Regadenoson—ADORA2A—Circadian rythm related genes—PPARA—prostate cancer	0.000397	0.00366	CbGpPWpGaD
Regadenoson—Discomfort—Capecitabine—prostate cancer	0.000397	0.000458	CcSEcCtD
Regadenoson—Vision blurred—Prednisone—prostate cancer	0.000396	0.000457	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—FGF10—prostate cancer	0.000395	0.00364	CbGpPWpGaD
Regadenoson—Feeling abnormal—Etoposide—prostate cancer	0.000394	0.000455	CcSEcCtD
Regadenoson—Diarrhoea—Mitoxantrone—prostate cancer	0.000393	0.000454	CcSEcCtD
Regadenoson—Vomiting—Estradiol—prostate cancer	0.000392	0.000453	CcSEcCtD
Regadenoson—Gastrointestinal pain—Etoposide—prostate cancer	0.000391	0.000451	CcSEcCtD
Regadenoson—Shock—Docetaxel—prostate cancer	0.000391	0.000451	CcSEcCtD
Regadenoson—Nervous system disorder—Docetaxel—prostate cancer	0.00039	0.00045	CcSEcCtD
Regadenoson—Ill-defined disorder—Prednisone—prostate cancer	0.00039	0.00045	CcSEcCtD
Regadenoson—Rash—Estradiol—prostate cancer	0.000389	0.000449	CcSEcCtD
Regadenoson—Dermatitis—Estradiol—prostate cancer	0.000389	0.000449	CcSEcCtD
Regadenoson—Tachycardia—Docetaxel—prostate cancer	0.000388	0.000448	CcSEcCtD
Regadenoson—Headache—Estradiol—prostate cancer	0.000387	0.000446	CcSEcCtD
Regadenoson—Skin disorder—Docetaxel—prostate cancer	0.000386	0.000445	CcSEcCtD
Regadenoson—Bradycardia—Epirubicin—prostate cancer	0.000384	0.000443	CcSEcCtD
Regadenoson—Angioedema—Prednisone—prostate cancer	0.000384	0.000443	CcSEcCtD
Regadenoson—Renal failure—Doxorubicin—prostate cancer	0.000382	0.000441	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—VAV3—prostate cancer	0.000382	0.00351	CbGpPWpGaD
Regadenoson—Urticaria—Etoposide—prostate cancer	0.00038	0.000438	CcSEcCtD
Regadenoson—Malaise—Prednisone—prostate cancer	0.000379	0.000437	CcSEcCtD
Regadenoson—Shock—Capecitabine—prostate cancer	0.000379	0.000437	CcSEcCtD
Regadenoson—Abdominal pain—Etoposide—prostate cancer	0.000378	0.000436	CcSEcCtD
Regadenoson—Nervous system disorder—Capecitabine—prostate cancer	0.000377	0.000435	CcSEcCtD
Regadenoson—ADORA2A—Circadian rythm related genes—LEP—prostate cancer	0.000377	0.00347	CbGpPWpGaD
Regadenoson—Syncope—Prednisone—prostate cancer	0.000377	0.000435	CcSEcCtD
Regadenoson—ADORA2A—GPCR ligand binding—PTHLH—prostate cancer	0.000376	0.00346	CbGpPWpGaD
Regadenoson—Tachycardia—Capecitabine—prostate cancer	0.000376	0.000433	CcSEcCtD
Regadenoson—Hypoaesthesia—Epirubicin—prostate cancer	0.000375	0.000433	CcSEcCtD
Regadenoson—Skin disorder—Capecitabine—prostate cancer	0.000374	0.000431	CcSEcCtD
Regadenoson—Hyperhidrosis—Capecitabine—prostate cancer	0.000372	0.000429	CcSEcCtD
Regadenoson—Hypotension—Docetaxel—prostate cancer	0.000371	0.000429	CcSEcCtD
Regadenoson—Connective tissue disorder—Epirubicin—prostate cancer	0.000371	0.000428	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—ITPR1—prostate cancer	0.00037	0.00341	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—MC2R—prostate cancer	0.00037	0.0034	CbGpPWpGaD
Regadenoson—Loss of consciousness—Prednisone—prostate cancer	0.000369	0.000426	CcSEcCtD
Regadenoson—Nausea—Estradiol—prostate cancer	0.000367	0.000423	CcSEcCtD
Regadenoson—Vomiting—Mitoxantrone—prostate cancer	0.000366	0.000422	CcSEcCtD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—ADRB2—prostate cancer	0.000364	0.00335	CbGpPWpGaD
Regadenoson—Convulsion—Prednisone—prostate cancer	0.000364	0.00042	CcSEcCtD
Regadenoson—Hypertension—Prednisone—prostate cancer	0.000363	0.000418	CcSEcCtD
Regadenoson—Rash—Mitoxantrone—prostate cancer	0.000363	0.000418	CcSEcCtD
Regadenoson—Dermatitis—Mitoxantrone—prostate cancer	0.000362	0.000418	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Docetaxel—prostate cancer	0.000362	0.000418	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—OR51E2—prostate cancer	0.000362	0.00333	CbGpPWpGaD
Regadenoson—Headache—Mitoxantrone—prostate cancer	0.00036	0.000416	CcSEcCtD
Regadenoson—Hypotension—Capecitabine—prostate cancer	0.00036	0.000415	CcSEcCtD
Regadenoson—Insomnia—Docetaxel—prostate cancer	0.000359	0.000415	CcSEcCtD
Regadenoson—Arthralgia—Prednisone—prostate cancer	0.000358	0.000413	CcSEcCtD
Regadenoson—Myalgia—Prednisone—prostate cancer	0.000358	0.000413	CcSEcCtD
Regadenoson—Paraesthesia—Docetaxel—prostate cancer	0.000357	0.000412	CcSEcCtD
Regadenoson—Anxiety—Prednisone—prostate cancer	0.000356	0.000411	CcSEcCtD
Regadenoson—Bradycardia—Doxorubicin—prostate cancer	0.000355	0.00041	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	0.000355	0.00041	CcSEcCtD
Regadenoson—Dyspnoea—Docetaxel—prostate cancer	0.000354	0.000409	CcSEcCtD
Regadenoson—Somnolence—Docetaxel—prostate cancer	0.000353	0.000408	CcSEcCtD
Regadenoson—Discomfort—Prednisone—prostate cancer	0.000353	0.000408	CcSEcCtD
Regadenoson—ADORA2A—GPCR ligand binding—ANXA1—prostate cancer	0.000353	0.00325	CbGpPWpGaD
Regadenoson—Eye disorder—Epirubicin—prostate cancer	0.000353	0.000407	CcSEcCtD
Regadenoson—Hypersensitivity—Etoposide—prostate cancer	0.000352	0.000407	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—WNT4—prostate cancer	0.000352	0.00324	CbGpPWpGaD
Regadenoson—Tinnitus—Epirubicin—prostate cancer	0.000352	0.000406	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Capecitabine—prostate cancer	0.000351	0.000405	CcSEcCtD
Regadenoson—Cardiac disorder—Epirubicin—prostate cancer	0.00035	0.000404	CcSEcCtD
Regadenoson—Flushing—Epirubicin—prostate cancer	0.00035	0.000404	CcSEcCtD
Regadenoson—Insomnia—Capecitabine—prostate cancer	0.000348	0.000402	CcSEcCtD
Regadenoson—Hypoaesthesia—Doxorubicin—prostate cancer	0.000347	0.000401	CcSEcCtD
Regadenoson—Paraesthesia—Capecitabine—prostate cancer	0.000346	0.000399	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—BAD—prostate cancer	0.000345	0.00317	CbGpPWpGaD
Regadenoson—Gastrointestinal disorder—Docetaxel—prostate cancer	0.000343	0.000396	CcSEcCtD
Regadenoson—Asthenia—Etoposide—prostate cancer	0.000343	0.000396	CcSEcCtD
Regadenoson—Connective tissue disorder—Doxorubicin—prostate cancer	0.000343	0.000396	CcSEcCtD
Regadenoson—Dyspnoea—Capecitabine—prostate cancer	0.000343	0.000396	CcSEcCtD
Regadenoson—Anaphylactic shock—Prednisone—prostate cancer	0.000343	0.000396	CcSEcCtD
Regadenoson—Angiopathy—Epirubicin—prostate cancer	0.000342	0.000395	CcSEcCtD
Regadenoson—Nausea—Mitoxantrone—prostate cancer	0.000342	0.000394	CcSEcCtD
Regadenoson—Immune system disorder—Epirubicin—prostate cancer	0.000341	0.000393	CcSEcCtD
Regadenoson—Mediastinal disorder—Epirubicin—prostate cancer	0.00034	0.000392	CcSEcCtD
Regadenoson—Pain—Docetaxel—prostate cancer	0.00034	0.000392	CcSEcCtD
Regadenoson—Shock—Prednisone—prostate cancer	0.000337	0.000389	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—PDGFRB—prostate cancer	0.000336	0.00309	CbGpPWpGaD
Regadenoson—Nervous system disorder—Prednisone—prostate cancer	0.000336	0.000388	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—MC2R—prostate cancer	0.000336	0.00309	CbGpPWpGaD
Regadenoson—Tachycardia—Prednisone—prostate cancer	0.000335	0.000386	CcSEcCtD
Regadenoson—Skin disorder—Prednisone—prostate cancer	0.000333	0.000384	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Capecitabine—prostate cancer	0.000332	0.000383	CcSEcCtD
Regadenoson—Hyperhidrosis—Prednisone—prostate cancer	0.000331	0.000382	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—BMPR1B—prostate cancer	0.000331	0.00305	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—CALCA—prostate cancer	0.000331	0.00304	CbGpPWpGaD
Regadenoson—Mental disorder—Epirubicin—prostate cancer	0.000331	0.000381	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—EGF—prostate cancer	0.00033	0.00303	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—IRS1—prostate cancer	0.00033	0.00303	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—PENK—prostate cancer	0.00033	0.00303	CbGpPWpGaD
Regadenoson—Pain—Capecitabine—prostate cancer	0.000329	0.00038	CcSEcCtD
Regadenoson—Erythema—Epirubicin—prostate cancer	0.000328	0.000379	CcSEcCtD
Regadenoson—Feeling abnormal—Docetaxel—prostate cancer	0.000328	0.000378	CcSEcCtD
Regadenoson—Diarrhoea—Etoposide—prostate cancer	0.000327	0.000378	CcSEcCtD
Regadenoson—ADORA2A—Circadian rythm related genes—GSK3B—prostate cancer	0.000327	0.003	CbGpPWpGaD
Regadenoson—Eye disorder—Doxorubicin—prostate cancer	0.000326	0.000377	CcSEcCtD
Regadenoson—Tinnitus—Doxorubicin—prostate cancer	0.000326	0.000376	CcSEcCtD
Regadenoson—Gastrointestinal pain—Docetaxel—prostate cancer	0.000325	0.000375	CcSEcCtD
Regadenoson—Flushing—Doxorubicin—prostate cancer	0.000324	0.000374	CcSEcCtD
Regadenoson—Cardiac disorder—Doxorubicin—prostate cancer	0.000324	0.000374	CcSEcCtD
Regadenoson—ADORA2A—GPCR ligand binding—CXCL12—prostate cancer	0.000323	0.00297	CbGpPWpGaD
Regadenoson—Dysgeusia—Epirubicin—prostate cancer	0.000322	0.000371	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—GSK3B—prostate cancer	0.00032	0.00295	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—ERBB3—prostate cancer	0.000318	0.00292	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—FGFR2—prostate cancer	0.000317	0.00292	CbGpPWpGaD
Regadenoson—Feeling abnormal—Capecitabine—prostate cancer	0.000317	0.000366	CcSEcCtD
Regadenoson—Angiopathy—Doxorubicin—prostate cancer	0.000317	0.000366	CcSEcCtD
Regadenoson—Dizziness—Etoposide—prostate cancer	0.000316	0.000365	CcSEcCtD
Regadenoson—Immune system disorder—Doxorubicin—prostate cancer	0.000315	0.000364	CcSEcCtD
Regadenoson—Gastrointestinal pain—Capecitabine—prostate cancer	0.000315	0.000363	CcSEcCtD
Regadenoson—Mediastinal disorder—Doxorubicin—prostate cancer	0.000315	0.000363	CcSEcCtD
Regadenoson—Abdominal pain—Docetaxel—prostate cancer	0.000314	0.000363	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Prednisone—prostate cancer	0.000312	0.00036	CcSEcCtD
Regadenoson—Insomnia—Prednisone—prostate cancer	0.00031	0.000358	CcSEcCtD
Regadenoson—Vision blurred—Epirubicin—prostate cancer	0.00031	0.000357	CcSEcCtD
Regadenoson—Paraesthesia—Prednisone—prostate cancer	0.000308	0.000355	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—RGS17—prostate cancer	0.000308	0.00283	CbGpPWpGaD
Regadenoson—Mental disorder—Doxorubicin—prostate cancer	0.000306	0.000353	CcSEcCtD
Regadenoson—Urticaria—Capecitabine—prostate cancer	0.000306	0.000353	CcSEcCtD
Regadenoson—Ill-defined disorder—Epirubicin—prostate cancer	0.000305	0.000352	CcSEcCtD
Regadenoson—Abdominal pain—Capecitabine—prostate cancer	0.000304	0.000351	CcSEcCtD
Regadenoson—Vomiting—Etoposide—prostate cancer	0.000304	0.000351	CcSEcCtD
Regadenoson—Erythema—Doxorubicin—prostate cancer	0.000304	0.000351	CcSEcCtD
Regadenoson—Rash—Etoposide—prostate cancer	0.000302	0.000348	CcSEcCtD
Regadenoson—Dermatitis—Etoposide—prostate cancer	0.000301	0.000348	CcSEcCtD
Regadenoson—Headache—Etoposide—prostate cancer	0.0003	0.000346	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—PENK—prostate cancer	0.000299	0.00275	CbGpPWpGaD
Regadenoson—Dysgeusia—Doxorubicin—prostate cancer	0.000298	0.000343	CcSEcCtD
Regadenoson—Malaise—Epirubicin—prostate cancer	0.000296	0.000342	CcSEcCtD
Regadenoson—ADORA2A—Circadian rythm related genes—SERPINE1—prostate cancer	0.000296	0.00272	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—MAP2K1—prostate cancer	0.000295	0.00272	CbGpPWpGaD
Regadenoson—Syncope—Epirubicin—prostate cancer	0.000295	0.00034	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—PIK3CD—prostate cancer	0.000293	0.0027	CbGpPWpGaD
Regadenoson—Hypersensitivity—Docetaxel—prostate cancer	0.000293	0.000338	CcSEcCtD
Regadenoson—Palpitations—Epirubicin—prostate cancer	0.00029	0.000335	CcSEcCtD
Regadenoson—Loss of consciousness—Epirubicin—prostate cancer	0.000289	0.000333	CcSEcCtD
Regadenoson—Cough—Epirubicin—prostate cancer	0.000287	0.000331	CcSEcCtD
Regadenoson—Vision blurred—Doxorubicin—prostate cancer	0.000286	0.000331	CcSEcCtD
Regadenoson—Asthenia—Docetaxel—prostate cancer	0.000285	0.000329	CcSEcCtD
Regadenoson—Convulsion—Epirubicin—prostate cancer	0.000285	0.000328	CcSEcCtD
Regadenoson—Nausea—Etoposide—prostate cancer	0.000284	0.000328	CcSEcCtD
Regadenoson—Hypertension—Epirubicin—prostate cancer	0.000284	0.000327	CcSEcCtD
Regadenoson—Hypersensitivity—Capecitabine—prostate cancer	0.000284	0.000327	CcSEcCtD
Regadenoson—Feeling abnormal—Prednisone—prostate cancer	0.000282	0.000326	CcSEcCtD
Regadenoson—Ill-defined disorder—Doxorubicin—prostate cancer	0.000282	0.000325	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—FGF2—prostate cancer	0.000281	0.00258	CbGpPWpGaD
Regadenoson—Gastrointestinal pain—Prednisone—prostate cancer	0.00028	0.000323	CcSEcCtD
Regadenoson—ADORA2A—GPCR downstream signaling—VIP—prostate cancer	0.00028	0.00258	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—GNRH1—prostate cancer	0.00028	0.00258	CbGpPWpGaD
Regadenoson—Chest pain—Epirubicin—prostate cancer	0.00028	0.000323	CcSEcCtD
Regadenoson—Myalgia—Epirubicin—prostate cancer	0.00028	0.000323	CcSEcCtD
Regadenoson—Arthralgia—Epirubicin—prostate cancer	0.00028	0.000323	CcSEcCtD
Regadenoson—Anxiety—Epirubicin—prostate cancer	0.000279	0.000322	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	0.000278	0.00032	CcSEcCtD
Regadenoson—ADORA2A—GPCR ligand binding—ADRB2—prostate cancer	0.000277	0.00255	CbGpPWpGaD
Regadenoson—Discomfort—Epirubicin—prostate cancer	0.000276	0.000319	CcSEcCtD
Regadenoson—Asthenia—Capecitabine—prostate cancer	0.000276	0.000319	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—RLN2—prostate cancer	0.000274	0.00252	CbGpPWpGaD
Regadenoson—Malaise—Doxorubicin—prostate cancer	0.000274	0.000316	CcSEcCtD
Regadenoson—Syncope—Doxorubicin—prostate cancer	0.000273	0.000315	CcSEcCtD
Regadenoson—Urticaria—Prednisone—prostate cancer	0.000272	0.000314	CcSEcCtD
Regadenoson—Diarrhoea—Docetaxel—prostate cancer	0.000272	0.000314	CcSEcCtD
Regadenoson—ADORA2A—GPCR downstream signaling—LPAR1—prostate cancer	0.000271	0.0025	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—GRP—prostate cancer	0.000271	0.0025	CbGpPWpGaD
Regadenoson—Abdominal pain—Prednisone—prostate cancer	0.000271	0.000313	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—JAK2—prostate cancer	0.000269	0.00248	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—PLCB2—prostate cancer	0.000269	0.00247	CbGpPWpGaD
Regadenoson—Palpitations—Doxorubicin—prostate cancer	0.000269	0.00031	CcSEcCtD
Regadenoson—Anaphylactic shock—Epirubicin—prostate cancer	0.000268	0.000309	CcSEcCtD
Regadenoson—Loss of consciousness—Doxorubicin—prostate cancer	0.000267	0.000308	CcSEcCtD
Regadenoson—Cough—Doxorubicin—prostate cancer	0.000265	0.000306	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—BAD—prostate cancer	0.000265	0.00244	CbGpPWpGaD
Regadenoson—Shock—Epirubicin—prostate cancer	0.000264	0.000304	CcSEcCtD
Regadenoson—Convulsion—Doxorubicin—prostate cancer	0.000263	0.000304	CcSEcCtD
Regadenoson—Diarrhoea—Capecitabine—prostate cancer	0.000263	0.000304	CcSEcCtD
Regadenoson—Nervous system disorder—Epirubicin—prostate cancer	0.000263	0.000303	CcSEcCtD
Regadenoson—Dizziness—Docetaxel—prostate cancer	0.000263	0.000303	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—MDM2—prostate cancer	0.000263	0.00242	CbGpPWpGaD
Regadenoson—Hypertension—Doxorubicin—prostate cancer	0.000262	0.000303	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—HSD17B1—prostate cancer	0.000262	0.00241	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CTBP2—prostate cancer	0.000262	0.00241	CbGpPWpGaD
Regadenoson—Tachycardia—Epirubicin—prostate cancer	0.000262	0.000302	CcSEcCtD
Regadenoson—Skin disorder—Epirubicin—prostate cancer	0.00026	0.0003	CcSEcCtD
Regadenoson—Hyperhidrosis—Epirubicin—prostate cancer	0.000259	0.000299	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—ERBB2—prostate cancer	0.000259	0.00238	CbGpPWpGaD
Regadenoson—Myalgia—Doxorubicin—prostate cancer	0.000259	0.000299	CcSEcCtD
Regadenoson—Chest pain—Doxorubicin—prostate cancer	0.000259	0.000299	CcSEcCtD
Regadenoson—Arthralgia—Doxorubicin—prostate cancer	0.000259	0.000299	CcSEcCtD
Regadenoson—Anxiety—Doxorubicin—prostate cancer	0.000258	0.000298	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	0.000257	0.000297	CcSEcCtD
Regadenoson—ADORA2A—GPCR downstream signaling—PDE4D—prostate cancer	0.000256	0.00236	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—PIK3CB—prostate cancer	0.000256	0.00235	CbGpPWpGaD
Regadenoson—Discomfort—Doxorubicin—prostate cancer	0.000256	0.000295	CcSEcCtD
Regadenoson—Dizziness—Capecitabine—prostate cancer	0.000254	0.000294	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—VIP—prostate cancer	0.000254	0.00234	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—GNRH1—prostate cancer	0.000254	0.00234	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—EGF—prostate cancer	0.000254	0.00233	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—IRS1—prostate cancer	0.000254	0.00233	CbGpPWpGaD
Regadenoson—Vomiting—Docetaxel—prostate cancer	0.000253	0.000292	CcSEcCtD
Regadenoson—Hypersensitivity—Prednisone—prostate cancer	0.000253	0.000291	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—PLXNB1—prostate cancer	0.000251	0.00231	CbGpPWpGaD
Regadenoson—Rash—Docetaxel—prostate cancer	0.000251	0.000289	CcSEcCtD
Regadenoson—Hypotension—Epirubicin—prostate cancer	0.000251	0.000289	CcSEcCtD
Regadenoson—Dermatitis—Docetaxel—prostate cancer	0.00025	0.000289	CcSEcCtD
Regadenoson—Headache—Docetaxel—prostate cancer	0.000249	0.000287	CcSEcCtD
Regadenoson—Anaphylactic shock—Doxorubicin—prostate cancer	0.000248	0.000286	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—GRP—prostate cancer	0.000246	0.00227	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—LPAR1—prostate cancer	0.000246	0.00227	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—GSK3B—prostate cancer	0.000246	0.00227	CbGpPWpGaD
Regadenoson—Asthenia—Prednisone—prostate cancer	0.000246	0.000284	CcSEcCtD
Regadenoson—Vomiting—Capecitabine—prostate cancer	0.000245	0.000282	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Epirubicin—prostate cancer	0.000244	0.000282	CcSEcCtD
Regadenoson—Shock—Doxorubicin—prostate cancer	0.000244	0.000282	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—PLCB2—prostate cancer	0.000244	0.00224	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—GNG5—prostate cancer	0.000244	0.00224	CbGpPWpGaD
Regadenoson—Nervous system disorder—Doxorubicin—prostate cancer	0.000243	0.000281	CcSEcCtD
Regadenoson—Rash—Capecitabine—prostate cancer	0.000243	0.00028	CcSEcCtD
Regadenoson—Insomnia—Epirubicin—prostate cancer	0.000242	0.00028	CcSEcCtD
Regadenoson—Dermatitis—Capecitabine—prostate cancer	0.000242	0.00028	CcSEcCtD
Regadenoson—Tachycardia—Doxorubicin—prostate cancer	0.000242	0.000279	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—GRPR—prostate cancer	0.000242	0.00222	CbGpPWpGaD
Regadenoson—Headache—Capecitabine—prostate cancer	0.000241	0.000278	CcSEcCtD
Regadenoson—Skin disorder—Doxorubicin—prostate cancer	0.000241	0.000278	CcSEcCtD
Regadenoson—Paraesthesia—Epirubicin—prostate cancer	0.000241	0.000278	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—CDKN1B—prostate cancer	0.00024	0.00221	CbGpPWpGaD
Regadenoson—Hyperhidrosis—Doxorubicin—prostate cancer	0.00024	0.000277	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—CX3CL1—prostate cancer	0.000239	0.0022	CbGpPWpGaD
Regadenoson—Dyspnoea—Epirubicin—prostate cancer	0.000239	0.000276	CcSEcCtD
Regadenoson—Somnolence—Epirubicin—prostate cancer	0.000238	0.000275	CcSEcCtD
Regadenoson—Nausea—Docetaxel—prostate cancer	0.000236	0.000272	CcSEcCtD
Regadenoson—Diarrhoea—Prednisone—prostate cancer	0.000235	0.000271	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—IL17RD—prostate cancer	0.000233	0.00215	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PDE4D—prostate cancer	0.000233	0.00214	CbGpPWpGaD
Regadenoson—Hypotension—Doxorubicin—prostate cancer	0.000232	0.000267	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Epirubicin—prostate cancer	0.000231	0.000267	CcSEcCtD
Regadenoson—Pain—Epirubicin—prostate cancer	0.000229	0.000265	CcSEcCtD
Regadenoson—Nausea—Capecitabine—prostate cancer	0.000229	0.000264	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—MAP2K1—prostate cancer	0.000227	0.00209	CbGpPWpGaD
Regadenoson—Dizziness—Prednisone—prostate cancer	0.000227	0.000262	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Doxorubicin—prostate cancer	0.000226	0.000261	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—PIK3CD—prostate cancer	0.000226	0.00208	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—PTEN—prostate cancer	0.000225	0.00207	CbGpPWpGaD
Regadenoson—Insomnia—Doxorubicin—prostate cancer	0.000224	0.000259	CcSEcCtD
Regadenoson—Paraesthesia—Doxorubicin—prostate cancer	0.000223	0.000257	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—CDKN1A—prostate cancer	0.000221	0.00204	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—GNG5—prostate cancer	0.000221	0.00204	CbGpPWpGaD
Regadenoson—Dyspnoea—Doxorubicin—prostate cancer	0.000221	0.000255	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—PTEN—prostate cancer	0.000221	0.00203	CbGpPWpGaD
Regadenoson—Feeling abnormal—Epirubicin—prostate cancer	0.000221	0.000255	CcSEcCtD
Regadenoson—Somnolence—Doxorubicin—prostate cancer	0.000221	0.000254	CcSEcCtD
Regadenoson—Gastrointestinal pain—Epirubicin—prostate cancer	0.000219	0.000253	CcSEcCtD
Regadenoson—Vomiting—Prednisone—prostate cancer	0.000218	0.000251	CcSEcCtD
Regadenoson—Rash—Prednisone—prostate cancer	0.000216	0.000249	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—FGF2—prostate cancer	0.000216	0.00199	CbGpPWpGaD
Regadenoson—Dermatitis—Prednisone—prostate cancer	0.000216	0.000249	CcSEcCtD
Regadenoson—ADORA2A—Circadian rythm related genes—EP300—prostate cancer	0.000215	0.00198	CbGpPWpGaD
Regadenoson—Headache—Prednisone—prostate cancer	0.000215	0.000248	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Doxorubicin—prostate cancer	0.000214	0.000247	CcSEcCtD
Regadenoson—Urticaria—Epirubicin—prostate cancer	0.000213	0.000246	CcSEcCtD
Regadenoson—ADORA2A—GPCR downstream signaling—PTHLH—prostate cancer	0.000212	0.00195	CbGpPWpGaD
Regadenoson—Pain—Doxorubicin—prostate cancer	0.000212	0.000245	CcSEcCtD
Regadenoson—Abdominal pain—Epirubicin—prostate cancer	0.000212	0.000245	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—JUP—prostate cancer	0.000208	0.00191	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—WNT4—prostate cancer	0.000208	0.00191	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—JAK2—prostate cancer	0.000207	0.00191	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—SRC—prostate cancer	0.000205	0.00189	CbGpPWpGaD
Regadenoson—Feeling abnormal—Doxorubicin—prostate cancer	0.000204	0.000236	CcSEcCtD
Regadenoson—Nausea—Prednisone—prostate cancer	0.000204	0.000235	CcSEcCtD
Regadenoson—Gastrointestinal pain—Doxorubicin—prostate cancer	0.000203	0.000234	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—MDM2—prostate cancer	0.000202	0.00186	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—ANXA1—prostate cancer	0.0002	0.00184	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—ERBB2—prostate cancer	0.000199	0.00183	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MC2R—prostate cancer	0.000198	0.00182	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—RALBP1—prostate cancer	0.000198	0.00182	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—STAT3—prostate cancer	0.000198	0.00182	CbGpPWpGaD
Regadenoson—Hypersensitivity—Epirubicin—prostate cancer	0.000198	0.000228	CcSEcCtD
Regadenoson—Urticaria—Doxorubicin—prostate cancer	0.000197	0.000227	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—PIK3CB—prostate cancer	0.000197	0.00181	CbGpPWpGaD
Regadenoson—Abdominal pain—Doxorubicin—prostate cancer	0.000196	0.000226	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—PTHLH—prostate cancer	0.000193	0.00177	CbGpPWpGaD
Regadenoson—Asthenia—Epirubicin—prostate cancer	0.000192	0.000222	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—PRKACB—prostate cancer	0.000189	0.00174	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—CALCA—prostate cancer	0.000187	0.00172	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—CDKN1B—prostate cancer	0.000185	0.0017	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PPP3CA—prostate cancer	0.000184	0.00169	CbGpPWpGaD
Regadenoson—Diarrhoea—Epirubicin—prostate cancer	0.000183	0.000212	CcSEcCtD
Regadenoson—Hypersensitivity—Doxorubicin—prostate cancer	0.000183	0.000211	CcSEcCtD
Regadenoson—ADORA2A—GPCR downstream signaling—CXCL12—prostate cancer	0.000183	0.00168	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—ANXA1—prostate cancer	0.000181	0.00167	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—CASP3—prostate cancer	0.000181	0.00166	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—EGFR—prostate cancer	0.00018	0.00165	CbGpPWpGaD
Regadenoson—Asthenia—Doxorubicin—prostate cancer	0.000178	0.000205	CcSEcCtD
Regadenoson—Dizziness—Epirubicin—prostate cancer	0.000177	0.000205	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—PENK—prostate cancer	0.000177	0.00163	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—prostate cancer	0.000176	0.00162	CbGpPWpGaD
Regadenoson—Vomiting—Epirubicin—prostate cancer	0.00017	0.000197	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—CDKN1A—prostate cancer	0.00017	0.00157	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—PTEN—prostate cancer	0.00017	0.00156	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CALCA—prostate cancer	0.00017	0.00156	CbGpPWpGaD
Regadenoson—Diarrhoea—Doxorubicin—prostate cancer	0.00017	0.000196	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—KRAS—prostate cancer	0.00017	0.00156	CbGpPWpGaD
Regadenoson—Rash—Epirubicin—prostate cancer	0.000169	0.000195	CcSEcCtD
Regadenoson—Dermatitis—Epirubicin—prostate cancer	0.000169	0.000195	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—GHR—prostate cancer	0.000169	0.00155	CbGpPWpGaD
Regadenoson—Headache—Epirubicin—prostate cancer	0.000168	0.000194	CcSEcCtD
Regadenoson—ADORA2A—GPCR downstream signaling—PRKCQ—prostate cancer	0.000167	0.00153	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CXCL12—prostate cancer	0.000166	0.00153	CbGpPWpGaD
Regadenoson—Dizziness—Doxorubicin—prostate cancer	0.000164	0.000189	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—NRP1—prostate cancer	0.000162	0.00149	CbGpPWpGaD
Regadenoson—Nausea—Epirubicin—prostate cancer	0.000159	0.000184	CcSEcCtD
Regadenoson—Vomiting—Doxorubicin—prostate cancer	0.000158	0.000182	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—SRC—prostate cancer	0.000158	0.00145	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—ADRB2—prostate cancer	0.000157	0.00144	CbGpPWpGaD
Regadenoson—Rash—Doxorubicin—prostate cancer	0.000156	0.00018	CcSEcCtD
Regadenoson—Dermatitis—Doxorubicin—prostate cancer	0.000156	0.00018	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—PIK3CA—prostate cancer	0.000156	0.00143	CbGpPWpGaD
Regadenoson—Headache—Doxorubicin—prostate cancer	0.000155	0.000179	CcSEcCtD
Regadenoson—ADORA2A—Circadian rythm related genes—TP53—prostate cancer	0.000154	0.00141	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—VAV3—prostate cancer	0.000153	0.00141	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—STAT3—prostate cancer	0.000152	0.0014	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PRKCQ—prostate cancer	0.000151	0.00139	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—VIP—prostate cancer	0.00015	0.00138	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—GNRH1—prostate cancer	0.00015	0.00138	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—ITPR1—prostate cancer	0.000148	0.00136	CbGpPWpGaD
Regadenoson—Nausea—Doxorubicin—prostate cancer	0.000147	0.00017	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—LPAR1—prostate cancer	0.000146	0.00134	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—GRP—prostate cancer	0.000146	0.00134	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PLCB2—prostate cancer	0.000144	0.00133	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—LRP2—prostate cancer	0.000144	0.00133	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—ADRB2—prostate cancer	0.000142	0.00131	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—P4HB—prostate cancer	0.000141	0.0013	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CX3CL1—prostate cancer	0.000141	0.0013	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—IL6—prostate cancer	0.000141	0.0013	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—VAV3—prostate cancer	0.000139	0.00128	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—HIST1H2BG—prostate cancer	0.000139	0.00128	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—EGFR—prostate cancer	0.000138	0.00127	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—IL6—prostate cancer	0.000138	0.00127	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—GRB7—prostate cancer	0.000137	0.00126	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PDE4D—prostate cancer	0.000137	0.00126	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—ITPR1—prostate cancer	0.000135	0.00124	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—HIST1H4H—prostate cancer	0.000134	0.00123	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—CXCL8—prostate cancer	0.000134	0.00123	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—GNG5—prostate cancer	0.000131	0.0012	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—KRAS—prostate cancer	0.00013	0.0012	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—AKT1—prostate cancer	0.000127	0.00117	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—PIK3CA—prostate cancer	0.00012	0.0011	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PTHLH—prostate cancer	0.000114	0.00105	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—TGFBR1—prostate cancer	0.000114	0.00105	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—AKR1C3—prostate cancer	0.000112	0.00103	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PRKACB—prostate cancer	0.000111	0.00103	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—THBS1—prostate cancer	0.000109	0.001	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PPP3CA—prostate cancer	0.000109	0.001	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—ANXA1—prostate cancer	0.000107	0.000985	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—IL6—prostate cancer	0.000106	0.000977	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PRKCZ—prostate cancer	0.000105	0.000967	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—PIK3CG—prostate cancer	0.000103	0.000945	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—FGFR4—prostate cancer	0.000102	0.000934	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PARP1—prostate cancer	0.000102	0.000934	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CALCA—prostate cancer	0.0001	0.000923	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CXCL12—prostate cancer	9.8e-05	0.000901	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—AKT1—prostate cancer	9.79e-05	0.000901	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PIK3CG—prostate cancer	9.33e-05	0.000859	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CASP9—prostate cancer	9.22e-05	0.000849	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—PIK3CD—prostate cancer	9.03e-05	0.000831	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PRKCQ—prostate cancer	8.94e-05	0.000822	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—NGFR—prostate cancer	8.94e-05	0.000822	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MAP3K7—prostate cancer	8.83e-05	0.000813	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—FGF10—prostate cancer	8.49e-05	0.000781	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—ADRB2—prostate cancer	8.4e-05	0.000773	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—JAK2—prostate cancer	8.29e-05	0.000763	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—MAP2K1—prostate cancer	8.26e-05	0.00076	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PIK3CD—prostate cancer	8.2e-05	0.000755	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—VAV3—prostate cancer	8.2e-05	0.000754	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—TGFBR2—prostate cancer	8.08e-05	0.000743	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—ITPR1—prostate cancer	7.95e-05	0.000731	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—PIK3CB—prostate cancer	7.87e-05	0.000724	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—IGF1R—prostate cancer	7.6e-05	0.000699	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—CXCL8—prostate cancer	7.57e-05	0.000696	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—JAK2—prostate cancer	7.53e-05	0.000693	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—LPL—prostate cancer	7.29e-05	0.00067	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—IL2—prostate cancer	7.23e-05	0.000665	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PDGFRB—prostate cancer	7.22e-05	0.000664	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PIK3CB—prostate cancer	7.15e-05	0.000658	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—ITGB3—prostate cancer	7.04e-05	0.000647	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CXCL8—prostate cancer	6.87e-05	0.000632	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—ERBB3—prostate cancer	6.83e-05	0.000628	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—FGFR2—prostate cancer	6.82e-05	0.000627	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—IL2—prostate cancer	6.57e-05	0.000604	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—TERT—prostate cancer	6.54e-05	0.000602	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—HIF1A—prostate cancer	6.26e-05	0.000576	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—LEP—prostate cancer	6.11e-05	0.000562	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CAV1—prostate cancer	6.05e-05	0.000557	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—KDR—prostate cancer	5.98e-05	0.000551	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—ESR1—prostate cancer	5.83e-05	0.000537	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—BAD—prostate cancer	5.69e-05	0.000524	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PIK3CG—prostate cancer	5.51e-05	0.000507	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—APC—prostate cancer	5.51e-05	0.000507	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—IRS1—prostate cancer	5.45e-05	0.000501	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—EGF—prostate cancer	5.45e-05	0.000501	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—GSK3B—prostate cancer	5.29e-05	0.000487	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—INS—prostate cancer	5.22e-05	0.00048	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CREBBP—prostate cancer	5.11e-05	0.00047	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—IGF1—prostate cancer	5.05e-05	0.000464	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—EGFR—prostate cancer	5.02e-05	0.000462	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MAP2K1—prostate cancer	4.88e-05	0.000449	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PIK3CD—prostate cancer	4.85e-05	0.000446	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—PIK3CA—prostate cancer	4.8e-05	0.000442	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—SERPINE1—prostate cancer	4.79e-05	0.000441	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—KRAS—prostate cancer	4.74e-05	0.000436	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—FGF2—prostate cancer	4.64e-05	0.000427	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—NOS3—prostate cancer	4.58e-05	0.000421	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—JAK2—prostate cancer	4.45e-05	0.000409	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PIK3CA—prostate cancer	4.36e-05	0.000401	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MDM2—prostate cancer	4.34e-05	0.000399	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—ERBB2—prostate cancer	4.28e-05	0.000394	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PIK3CB—prostate cancer	4.22e-05	0.000389	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CXCL8—prostate cancer	4.06e-05	0.000373	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CDKN1B—prostate cancer	3.96e-05	0.000365	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—AKT1—prostate cancer	3.92e-05	0.000361	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CASP3—prostate cancer	3.88e-05	0.000357	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—IL2—prostate cancer	3.88e-05	0.000357	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—IL6—prostate cancer	3.86e-05	0.000355	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CCND1—prostate cancer	3.78e-05	0.000348	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CTNNB1—prostate cancer	3.74e-05	0.000345	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MMP9—prostate cancer	3.67e-05	0.000338	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CDKN1A—prostate cancer	3.66e-05	0.000337	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PTEN—prostate cancer	3.65e-05	0.000336	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—AKT1—prostate cancer	3.56e-05	0.000328	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—EP300—prostate cancer	3.48e-05	0.00032	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—SRC—prostate cancer	3.38e-05	0.000311	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—VEGFA—prostate cancer	3.3e-05	0.000303	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—STAT3—prostate cancer	3.26e-05	0.0003	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MYC—prostate cancer	3.03e-05	0.000279	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—TGFB1—prostate cancer	3.03e-05	0.000278	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—EGFR—prostate cancer	2.97e-05	0.000273	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—KRAS—prostate cancer	2.8e-05	0.000258	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PIK3CA—prostate cancer	2.57e-05	0.000237	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—TP53—prostate cancer	2.49e-05	0.000229	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—IL6—prostate cancer	2.28e-05	0.00021	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—AKT1—prostate cancer	2.1e-05	0.000194	CbGpPWpGaD
